Flerie (FLERIE.ST) Stock Analysis & AI Equity Report
Flerie (FLERIE.ST) overview
Flerie (FLERIE.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Flerie reported revenue of SEK 0.1m and operating profit of SEK -111m; the year-end share price was 46.95 SEK and market capitalisation was SEK 3,309m. Flerie is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Flerie's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About Flerie
Flerie is a long-term life science investor focused on biotechnology and pharmaceutical companies. It invests globally in private businesses, with positions in product development and commercial growth, and also makes selective investments in public companies and funds. The company aims to support portfolio development through active ownership, network access, and operational resources.
Generate the Flerie report
Flerie is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Flerie and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.